Global Antibody Drug Conjugates (ADC) Market, By Target (Antibody-Protein Toxin Conjugates, Antibody-Chelated Radionuclide Conjugates, Antibody-Small-Molecule Drug Conjugates, Antibody-Enzyme Conjugates), Product (Adcertis, Kadcyla, Others), Mechanism of Action (CD30 Antibodies, HER2 Antibodies), Technology (Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Others), Indication (Lymphoma, Breast Cancer, Brain Tumor, Lung Cancer, Ovarian Cancer, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Antibody Drug Conjugates (ADC) Market
Antibody drug conjugates (ADC) market size is projected to grow at a compound annual growth rate of 23.7% over the forecast period of 2022 to 2029. Data Bridge Market Research report on antibody drug conjugates (ADC) market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.
Antibody drug conjugates are basically the biopharmaceuticals agents that are manufactured for targeted therapy of cancer treatment. They are covalently linked to the antibody or antibody fragment that directed towards the specific cell surface target expressed on the tumor cells. They are combined with monoclonal antibodies to target the cancer cells and act by specifically targeting to the tumor antigen surface, the complex internalized into the cells.
The factors such as rising prevalence of cancer related disorders worldwide and emerging markets across the globe are expected to accelerate the market growth in the forecast period of 2022 to 2029. Furthermore, the increased research and clinical trials and growing cases of breast cancer in female will further carve the way for the growth of the market. However, the stringent FDA guidelines for the drug approval of new drug is projected to restraint the market growth rate. On the other hand, the adverse effect after the treatment in some cases also hampers the overall growth of the market.
In addition, the increase in product launches and approvals by market players along with increasing number of research and development activities are likely to create various new opportunities that will impact this antibody drug conjugates (ADC) market growth in the forecast period of 2022 to 2029. The low awareness regarding these biopharmaceuticals agents is estimated to challenge the market’s growth.
This antibody drug conjugates (ADC) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the antibody drug conjugates (ADC) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Antibody Drug Conjugates (ADC) Market Scope and Market Size
Antibody drug conjugates (ADC) market is segmented on the basis of target, product, mechanism of action, technology, indication, end-users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of target, the market is segmented into antibody-protein toxin conjugates, antibody-chelated radionuclide conjugates, antibody-small-molecule drug conjugates and antibody-enzyme conjugates.
- On the basis of product, the market is segmented into adcertis, kadcyla and others.
- On the basis of mechanism of action, the market is segmented into cd30 antibodies and her2 antibodies.
- On the basis of technology, the market is segmented into immunogen technology, seattle genetics technology, immunomedics technology and others.
- The indication for antibody drug conjugates (ADC) market includes lymphoma, breast cancer, brain tumor, lung cancer, ovarian cancer and others.
- On the basis of end-users, the market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, the market has also been segmented into hospital pharmacy, retail pharmacy and others.
Antibody Drug Conjugates (ADC) Market Country Level Analysis
Antibody drug conjugates (ADC) market is analyzed and market size information is provided by target, product, mechanism of action, technology, indication, end-users and distribution channel.as referenced above.
The countries covered in the antibody drug conjugates (ADC) market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the antibody drug conjugates (ADC) market due to the presence of key manufacture of the product, high research and development and healthcare expenditure and skilled professionals in this region. Asia-Pacific region, on the other hand is expected to expand at a significant growth rate because of the increased government awareness programs and number of generic drugs and rising cancer and bone marrow surgeries within the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Antibody drug conjugates (ADC) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Antibody Drug Conjugates (ADC) Market Share Analysis
Antibody drug conjugates (ADC) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to antibody drug conjugates (ADC) market.
Some of the major players operating in the antibody drug conjugates (ADC) market report are Seagen Inc., Genentech Inc., Pfizer Inc., Novartis AG, F. Hoffmann-LA Roche Ltd., Bristol -Myers Squibb, Merck & Co., Inc. Immunomedics Inc., Takeda Pharmaceutical Company Limited, Onconova Therapeutics, Helsinn Healthcare SA, Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited, DAIICHI SANKYO COMPANY, LIMITED., and AbbVie Inc., among others.
Customization Available : Global Antibody Drug Conjugates (ADC) Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.